{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:44:29Z","timestamp":1773366269678,"version":"3.50.1"},"reference-count":45,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.1248\/bpb.b24-00794","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:15:21Z","timestamp":1738361721000},"page":"93-100","source":"Crossref","is-referenced-by-count":3,"title":["Activated Fibroblast Growth Factor Receptor 1 Mitigated Poly-PR\u2013Induced Oxidative Stress and Protein Translational Impairment"],"prefix":"10.1248","volume":"48","author":[{"given":"Taisei","family":"Ito","sequence":"first","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"},{"name":"Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Ohuchi","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaka","family":"Kurita","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Murakami","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinnosuke","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Murata","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Oida","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoyuki","family":"Kitaichi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Inden","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1\u201325\u20134 Daigaku-nishi, Gifu 501\u20131196, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Julien J-P. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell<\/i>, 104<\/b>, 581\u2013591 (2001).","DOI":"10.1016\/S0092-8674(01)00244-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Norris SP, Likanje MFN, Andrews JA. Amyotrophic lateral sclerosis: Update on clinical management. Curr. Opin. Neurol<\/i>., 33<\/b>, 641\u2013648 (2020).","DOI":"10.1097\/WCO.0000000000000864"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kumar R, Haider S. Protein network analysis to prioritize key genes in amyotrophic lateral sclerosis. IBRO Neurosci. Rep<\/i>., 12<\/b>, 25\u201344 (2022).","DOI":"10.1016\/j.ibneur.2021.12.002"},{"key":"4","unstructured":"4) Renton AE, Majounie E, Waite A, et al<\/i>. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron<\/i>, 72<\/b>, 257\u2013268 (2011)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al<\/i>. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron<\/i>, 72<\/b>, 245\u2013256 (2011).","DOI":"10.1016\/j.neuron.2011.09.011"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D, Neumann M. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol<\/i>., 126<\/b>, 859\u2013879 (2013).","DOI":"10.1007\/s00401-013-1181-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol<\/i>., 14<\/b>, 544\u2013558 (2018).","DOI":"10.1038\/s41582-018-0047-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Smeele PH, Cesare G, Vaccari T. ALS\u2019 perfect storm: C9orf72<\/i>-associated toxic dipeptide repeats as potential multipotent disruptors of protein homeostasis. Cells<\/i>, 13<\/b>, 178 (2024).","DOI":"10.3390\/cells13020178"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, Pasinelli P, Ichida JK, Trotti D. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS\/FTD form toxic nuclear aggregates that initiate in vitro<\/i> and in vivo<\/i> neuronal death. Neuron<\/i>, 84<\/b>, 1213\u20131225 (2014).","DOI":"10.1016\/j.neuron.2014.12.010"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Fu RH. Pectolinarigenin improves oxidative stress and apoptosis in mouse NSC-34 motor neuron cell lines induced by C9-ALS-associated proline-arginine dipeptide repeat proteins by enhancing mitochondrial fusion mediated via<\/i> the SIRT3\/OPA1 axis. Antioxidants<\/i>, 12<\/b>, 2008 (2023).","DOI":"10.3390\/antiox12112008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, Miller TM, Urano F. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum. Mol. Genet<\/i>., 25<\/b>, 1803\u20131813 (2016).","DOI":"10.1093\/hmg\/ddw052"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hartmann H, Hornburg D, Czuppa M, Bader J, Michaelsen M, Farny D, Arzberger T, Mann M, Meissner F, Edbauer D. Proteomics and C9orf72<\/i> neuropathology identify ribosomes as poly-GR\/PR interactors driving toxicity. Life Sci. Alliance<\/i>, 1<\/b>, e201800070 (2018).","DOI":"10.26508\/lsa.201800070"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yin S, Lopez-Gonzalez R, Kunz RC, Gangopadhyay J, Borufka C, Gygi SP, Gao FB, Reed R. Evidence that C9ORF72<\/i> dipeptide repeat proteins associate with U2 snRNP to cause mis-splicing in ALS\/FTD patients. Cell Rep<\/i>., 19<\/b>, 2244\u20132256 (2017).","DOI":"10.1016\/j.celrep.2017.05.056"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Burk K, Pasterkamp RJ. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol<\/i>., 137<\/b>, 859\u2013877 (2019).","DOI":"10.1007\/s00401-019-01964-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J, Kolaitis RM, Shaw TI, Bai B, Peng J, Kriwacki RW, Taylor JP. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell<\/i>, 167<\/b>, 774\u2013788.e17 (2016).","DOI":"10.1016\/j.cell.2016.10.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Boeynaems S, Bogaert E, Kovacs D, et al<\/i>. Phase separation of C9orf72<\/i> dipeptide repeats perturbs stress granule dynamics. Mol. Cell<\/i>, 65<\/b>, 1044\u20131055.e5 (2017).","DOI":"10.1016\/j.molcel.2017.02.013"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mizielinska S, Ridler CE, Balendra R, Thoeng A, Woodling NS, Gr\u00e4sser FA, Plagnol V, Lashley T, Partridge L, Isaacs AM. Bidirectional nucleolar dysfunction in C9orf72<\/i> frontotemporal lobar degeneration. Acta Neuropathol. Commun<\/i>., 5<\/b>, 29 (2017).","DOI":"10.1186\/s40478-017-0432-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature<\/i>, 443<\/b>, 787\u2013795 (2006).","DOI":"10.1038\/nature05292"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gomez-Suaga P, M\u00f3rotz GM, Markovinovic A, Mart\u00edn-Guerrero SM, Preza E, Arias N, Mayl K, Aabdien A, Gesheva V, Nishimura A, Annibali A, Lee Y, Mitchell JC, Wray S, Shaw C, Noble W, Miller CCJ. Disruption of ER-mitochondria tethering and signalling in C9orf72<\/i>-associated amyotrophic lateral sclerosis and frontotemporal dementia. Aging Cell<\/i>, 21<\/b>, e13549 (2022).","DOI":"10.1111\/acel.13549"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Alvarez-Mora MI, Garrabou G, Barcos T, Garcia-Garcia F, Grillo-Risco R, Peruga E, Gort L, Borrego-\u00e9cija S, Sanchez-Valle R, Canto-Santos J, Navarro-Navarro P, Rodriguez-Revenga L. Bioenergetic and autophagic characterization of skin fibroblasts from C9orf72<\/i> patients. Antioxidants<\/i>, 11<\/b>, 1129 (2022).","DOI":"10.3390\/antiox11061129"},{"key":"21","unstructured":"21) Abe K, Aoki M, Tsuji S, et al<\/i>. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol<\/i>., 16<\/b>, 505\u2013512 (2017)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Shou L, Bei Y, Song Y, Wang L, Ai L, Yan Q, He W. Nrf2 mediates the protective effect of edaravone after chlorpyrifos-induced nervous system toxicity. Environ. Toxicol<\/i>., 34<\/b>, 626\u2013633 (2019).","DOI":"10.1002\/tox.22728"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Jim\u00e9nez-Villegas J, Kirby J, Mata A, Cadenas S, Turner MR, Malaspina A, Shaw PJ, Cuadrado A, Rojo AI. Dipeptide repeat pathology in C9orf72<\/i>-ALS is associated with redox, mitochondrial and NRF2 pathway imbalance. Antioxidants<\/i>, 11<\/b>, 1897 (2022).","DOI":"10.3390\/antiox11101897"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol<\/i>., 4<\/b>, 215\u2013266 (2015).","DOI":"10.1002\/wdev.176"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Klimaschewski L, Claus P. Fibroblast growth factor signalling in the diseased nervous system. Mol. Neurobiol<\/i>., 58<\/b>, 3884\u20133902 (2021).","DOI":"10.1007\/s12035-021-02367-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Sapieha PS, Peltier M, Rendahl KG, Manning WC, Di Polo A. Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury. Mol. Cell. Neurosci<\/i>., 24<\/b>, 656\u2013672 (2003).","DOI":"10.1016\/S1044-7431(03)00228-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer\u2019s disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U.S.A<\/i>., 108<\/b>, E1339\u2013E1348 (2011).","DOI":"10.1073\/pnas.1102349108"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Fang X, Ma J, Mu D, Li B, Lian B, Sun C. FGF21 protects dopaminergic neurons in Parkinson\u2019s disease models via<\/i> repression of neuroinflammation. Neurotox. Res<\/i>., 37<\/b>, 616\u2013627 (2020).","DOI":"10.1007\/s12640-019-00151-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Gong Z, Gao L, Guo J, Lu Y, Zang D. bFGF in the CSF and serum of sALS patients. Acta Neurol. Scand<\/i>., 132<\/b>, 171\u2013178 (2015).","DOI":"10.1111\/ane.12381"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Liu B, Lyu L, Zhou W, Song J, Ye D, Mao Y, Chen GB, Sun X. Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis: a Mendelian randomization study. BMC Med<\/i>., 21<\/b>, 39 (2023).","DOI":"10.1186\/s12916-023-02736-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Yu Z, Lin L, Jiang Y, Chin I, Wang X, Li X, Lo EH, Wang X. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol. Neurobiol<\/i>., 56<\/b>, 2314\u20132327 (2019).","DOI":"10.1007\/s12035-018-1234-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Suh J, Kim D-H, Kim S-J, Cho N-C, Lee Y-H, Jang J-H, Surh Y-J. Nuclear localization of fibroblast growth factor receptor 1 in breast cancer cells interacting with cancer associated fibroblasts. J. Cancer Prev<\/i>., 27<\/b>, 68\u201376 (2022).","DOI":"10.15430\/JCP.2022.27.1.68"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Yamaji M, Jishage M, Meyer C, Suryawanshi H, Der E, Yamaji M, Garzia A, Morozov P, Manickavel S, McFarland HL, Roeder RG, Hafner M, Tuschl T. DND1 maintains germline stem cells via<\/i> recruitment of the CCR4-NOT complex to target mRNAs. Nature<\/i>, 543<\/b>, 568\u2013572 (2017).","DOI":"10.1038\/nature21690"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Eggett CJ, Crosier S, Manning P, Cookson MR, Menzies FM, Mcneil CJ, Shaw PJ. Development and characterisation of a glutamate-sensitive motor neurone cell line. J. Neurochem<\/i>., 74<\/b>, 1895\u20131902 (2000).","DOI":"10.1046\/j.1471-4159.2000.0741895.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hiroi A, Yamamoto T, Shibata N, Osawa M, Kobayashi M. Roles of fukutin, the gene responsible for Fukuyama-type congenital muscular dystrophy, in neurons: possible involvement in synaptic function and neuronal migration. Acta Histochem. Cytochem<\/i>., 44<\/b>, 91\u2013101 (2011).","DOI":"10.1267\/ahc.10045"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Nguyen TM, Kabotyanski EB, Dou Y, Reineke LC, Zhang P, Zhang XHF, Malovannaya A, Jung SY, Mo Q, Roarty KP, Chen Y, Zhang B, Neilson JR, Lloyd RE, Perou CM, Ellis MJ, Rosen JM. FGFR1-activated translation of WNT pathway components with structured 5\u2032 UTRs is vulnerable to inhibition of EIF4A-dependent translation initiation. Cancer Res<\/i>., 78<\/b>, 4229\u20134240 (2018).","DOI":"10.1158\/0008-5472.CAN-18-0631"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Chuang JI, Huang JY, Tsai SJ, Sun HS, Yang SH, Chuang PC, Huang BM, Ching CH. FGF9-induced changes in cellular redox status and HO-1 upregulation are FGFR-dependent and proceed through both ERK and AKT to induce CREB and Nrf2 activation. Free Radic. Biol. Med<\/i>., 89<\/b>, 274\u2013286 (2015).","DOI":"10.1016\/j.freeradbiomed.2015.08.011"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ku\u017ama-Kozakiewicz M. Edaravone in the treatment of amyotrophic lateral sclerosis. Neurol. Neurochir. Pol<\/i>., 52<\/b>, 124\u2013128 (2018).","DOI":"10.1016\/j.pjnns.2018.03.004"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Maor-Nof M, Shipony Z, Lopez-Gonzalez R, et al<\/i>. p53 is a central regulator driving neurodegeneration caused by C9orf72<\/i> poly(PR). Cell<\/i>, 184<\/b>, 689\u2013708.e20 (2021).","DOI":"10.1016\/j.cell.2020.12.025"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Jung CR, Lim JH, Choi Y, Kim DG, Kang KJ, Noh SM, Im DS. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J. Clin. Invest<\/i>., 120<\/b>, 4493\u20134506 (2010).","DOI":"10.1172\/JCI42674"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Coutu DL, Galipeau J. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY)<\/i>, 3<\/b>, 920\u2013933 (2011).","DOI":"10.18632\/aging.100369"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Goddard DR, Berry M, Kirvell SL, Butt AM. Fibroblast growth factor-2 induces astroglial and microglial reactivity in vivo<\/i>. J. Anat<\/i>., 200<\/b>, 57\u201367 (2002).","DOI":"10.1046\/j.0021-8782.2001.00002.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Zou LH, Shi YJ, He H, Jiang SM, Huo FF, Wang XM, Wu F, Ma L. Effects of FGF2\/FGFR1 pathway on expression of A1 astrocytes after infrasound exposure. Front. Neurosci<\/i>., 13<\/b>, 429 (2019).","DOI":"10.3389\/fnins.2019.00429"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J. Regulation of glial glutamate transporter expression by growth factors. Exp. Neurol<\/i>., 183<\/b>, 124\u2013135 (2003).","DOI":"10.1016\/S0014-4886(03)00134-1"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Morioka N, Harano S, Tokuhara M, Idenoshita Y, Zhang FF, Hisaoka-Nakashima K, Nakata Y. Stimulation of \u03b1<\/i>7 nicotinic acetylcholine receptor regulates glutamate transporter GLAST via<\/i> basic fibroblast growth factor production in cultured cortical microglia. Brain Res<\/i>., 1625<\/b>, 111\u2013120 (2015).","DOI":"10.1016\/j.brainres.2015.08.029"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/2\/48_b24-00794\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:30:20Z","timestamp":1738380620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/2\/48_b24-00794\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00794","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"article-number":"b24-00794"}}